<DOC>
	<DOCNO>NCT00902538</DOCNO>
	<brief_summary>Both Olmesartan ( OLM ) /Amlodipine ( AML ) combination Hydrochlorothiazide ( HCTZ ) proven efficacious safe lower blood pressure , may always sufficient . This study test efficacy safety combination OLM/AML HCTZ hypertensive patient whose blood pressure adequately control OLM/AML alone . The following treatment include trial : OLM 40mg/AML 10mg ; OLM 40mg/AML 10 mg/HCTZ 12.5 mg ; OLM 40 mg/AML 10 mg/HCTZ 25 mg . The trial four period . The treatment use follow : Period 1 - OLM 40mg/AML 10mg ; Period 2 - OLM 40mg/AML 10mg OLM 40mg/AML 10 mg/HCTZ 12.5 mg OLM 40 mg/AML 10 mg/HCTZ 25 mg ; Period 3 - OLM 40mg/AML 10 mg/HCTZ 12.5 mg ; Period 4 - Period 3 responder : OLM 40mg/AML 10 mg/HCTZ 12.5 mg ; Period 4 - Period 3 non-responders : OLM 40mg/AML 10 mg/HCTZ 12.5 mg OLM 40 mg/AML 10 mg/HCTZ 25 mg</brief_summary>
	<brief_title>Hydrochlorothiazide add-on Olmesartan/Amlodipine Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female age 18 year old . Mean trough seat systolic blood pressure ( SeSBP ) ≥ 160/100 mmHg ( SeSBP ≥ 160 mmHg seat diastolic blood pressure ( SeDBP ) ≥ 100 mmHg ) screen currently antihypertensive medication ( e.g . newly diagnose subject ) OR : For subject monotherapy : mean trough SeSBP ≥ 150/95 mmHg ( SeSBP ≥ 150 mmHg SeDBP ≥ 95 mmHg ) screening OR : For subject combination antihypertensive medication include either hydrochlorothiazide amlodipine olmesartan duration least four week : mean trough SeSBP ≥ 140/90 mmHg ( SeSBP ≥ 140 mmHg SeDBP ≥ 90 mmHg ) screening OR : For subject combination antihypertensive medication include neither hydrochlorothiazide , amlodipine olmesartan : mean trough SeSBP ≥ 160 mmHg , mean trough SeDBP ≥ 100mmHg , end taperoff period Subject freely sign Informed Consent Form ( ICF ) nature study disclosure his/her data explain . Female subject childbearing potential must use adequate contraception ( female childbearing potential define one postmenopausal least one year , surgically sterilise , hysterectomy least three month prior start study [ Visit 1 ] ) . Females take oral contraceptive therapy least three month . Adequate contraceptive include hormonal intrauterine device , hormonal contraceptive ( oral , depot , patch injectable ) , double barrier method condom diaphragms spermicidal gel foam . If female becomes pregnant study , withdrawn immediately . Female subject childbearing potential pregnant lactating . Subjects serious disorder may limit ability evaluate efficacy safety investigational product , include cerebrovascular , cardiovascular , renal , respiratory , hepatic , gastrointestinal , endocrine metabolic , haematological oncological , neurological , psychiatric disease . The applies immunocompromised and/or neutropenic subject . Subjects history follow within last six month : myocardial infarction ( MI ) , unstable angina pectoris , percutaneous coronary intervention , heart failure , hypertensive encephalopathy , cerebrovascular accident ( stroke ) , transient ischaemic attack . Subjects clinically significant abnormal laboratory value Screening , include subject one following : Aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 3 time ULN Gammaglutamyltransferase ( GGT ) &gt; 3 time ULN Potassium ULN ( unless high value due haemolytic blood sample ) Subjects secondary hypertension aetiology renal disease , phaeochromocytoma , Cushing 's syndrome . Subjects contraindication olmesartan , amlodipine , hydrochlorothiazide , excipients . Subjects mean SeSBP &gt; 200 mmHg mean SeDBP &gt; 115 mmHg bradycardia ( heart rate &lt; 50 beats/min rest document mean radial pulse rate [ PR ] electrocardiogram [ ECG ] ) Screening ( Visit 1 ) immediately take Period I study medication ( Visit 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Add treatment</keyword>
	<keyword>essential hypertension</keyword>
</DOC>